BACKGROUND: HerpeSelect HSV-1 and HSV-2 ELISAs are glycoprotein G-based, type-specific antibody detection tests that are approved by the US Food and Drug Administration for diagnosis of genital herpes. GOAL: The goal was to determine seroconversion times by means of HerpeSelect ELISAs. STUDY DESIGN: Four-hundred thirteen sera from 113 patients with recently acquired genital herpes were tested by HerpeSelect ELISAs and Western blot (WB). Thirty-one patients had primary genital HSV-1 (group 1), 56 had primary HSV-2 (group 2), and 26 had prior HSV-1 antibodies and newly acquired HSV-2 (group 3). RESULTS: Median interval from onset of symptoms to seroconversion was 25 days, as determined by HerpeSelect HSV-1, versus 33 days by WB for group 1; 21 days by HerpeSelect HSV-2 versus 40 days by WB (group 2; P = 0.0005); and 23 days by HerpeSelect HSV-2 ELISA versus 47 days by WB (group 3; P = 0.02). In long-term follow-up, transient reversion to HerpeSelect negativity occurred in 3 of 31 HSV-1-infected subjects (10%) and in 2 of 82 HSV-2-infected subjects (2%). CONCLUSION: Seroconversion to HSV-2 was determined faster by HerpeSelect than by WB.
BACKGROUND: HerpeSelect HSV-1 and HSV-2 ELISAs are glycoprotein G-based, type-specific antibody detection tests that are approved by the US Food and Drug Administration for diagnosis of genital herpes. GOAL: The goal was to determine seroconversion times by means of HerpeSelect ELISAs. STUDY DESIGN: Four-hundred thirteen sera from 113 patients with recently acquired genital herpes were tested by HerpeSelect ELISAs and Western blot (WB). Thirty-one patients had primary genital HSV-1 (group 1), 56 had primary HSV-2 (group 2), and 26 had prior HSV-1 antibodies and newly acquired HSV-2 (group 3). RESULTS: Median interval from onset of symptoms to seroconversion was 25 days, as determined by HerpeSelect HSV-1, versus 33 days by WB for group 1; 21 days by HerpeSelect HSV-2 versus 40 days by WB (group 2; P = 0.0005); and 23 days by HerpeSelect HSV-2 ELISA versus 47 days by WB (group 3; P = 0.02). In long-term follow-up, transient reversion to HerpeSelect negativity occurred in 3 of 31 HSV-1-infected subjects (10%) and in 2 of 82 HSV-2-infected subjects (2%). CONCLUSION: Seroconversion to HSV-2 was determined faster by HerpeSelect than by WB.
Authors: Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies Journal: J Virol Date: 2012-02-08 Impact factor: 5.103
Authors: J Lingappa; E Nakku-Joloba; A Magaret; D Friedrich; J Dragavon; F Kambugu; M Joloba; C Whalen; R Coombs; C Celum; R Ashley Morrow Journal: Int J STD AIDS Date: 2010-09 Impact factor: 1.359
Authors: Hayley D Mark; Joy P Nanda; Jessica Roberts; Anne Rompalo; Johan H Melendez; Jonathan Zenilman Journal: Sex Transm Dis Date: 2007-09 Impact factor: 2.830
Authors: Musa Otieno Ng'ayo; David Friedrich; King K Holmes; Elizabeth Bukusi; Rhoda Ashley Morrow Journal: J Virol Methods Date: 2009-10-23 Impact factor: 2.014
Authors: Ann J Melvin; Kathleen M Mohan; Joshua T Schiffer; Linda M Drolette; Amalia Magaret; Lawrence Corey; Anna Wald Journal: J Pediatr Date: 2014-12-06 Impact factor: 4.406
Authors: J S Smith; R C Bailey; D J Westreich; I Maclean; K Agot; J O Ndinya-Achola; W Hogrefe; R A Morrow; S Moses Journal: Sex Transm Infect Date: 2008-10-27 Impact factor: 3.519